Gemcitabine and carboplatin in second-line ovarian cancer

Seminars in Oncology

Volumn 32, Issue SUPPL. 6, 2005, Pages 4-

  Ozols, Robert F ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE; TOPOTECAN;

ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; FEBRILE NEUTROPENIA; HUMAN; INFECTION; NEUROTOXICITY; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; SENSORY DYSFUNCTION; SIDE EFFECT;

EID: 24144440415     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.06.023     Document Type: Article

References (30)

1. A. Jemal, T. Murray, E. Ward Cancer statistics, 2005 CA Cancer J Clin 55 2005 10 30
2. B.A. Goff, L.S. Mandel, C.H. Melancon Frequency of symptoms of ovarian cancer in women presenting to primary care clinics JAMA 291 2004 2705 2712
3. M.B. Daly, R.F. Ozols Symptoms of ovarian cancer - Where to set the bar? JAMA 291 2004 2755 2756
4. R.F. Ozols Advanced ovarian cancer A clinical update on first-line treatment, recurrent disease and new agents J NCCN 2 2004 S60 S73
5. R.F. Ozols, B.N. Bundy, B.E. Greer Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer A Gynecologic Oncology Group study J Clin Oncol 21 2003 3194 3200
6. A. duBois, H.-J. Lück, W. Meier A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J Natl Cancer Inst 95 2003 1320 1330
7. M.A. Bookman Developmental chemotherapy and management of recurrent ovarian cancer J Clin Oncol 21 2003 149s 167s
8. The ICON and AGO Collaborators Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer The ICON4/AGO-OVAR-2.2 trial Lancet 361 2003 2099 2106
9. J. Pfisterer, M. Plante, I. Vergote Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum-sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG Proc Am Soc Clin Oncol 23 2004 449 (abstr 5005)
10. A.N. Gordon, M. Tonda, S. Sun Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer Gynecol Oncol 95 2004 1 8
11. G.J.S. Rustin, R.C. Bast, G.J. Kelloff Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer Clin Cancer Res 10 2004 3919 3926
12. G.J. Rustin, A.E. Nelstrop, P. McClean Defining response of ovarian carcinoma to initial chemotherapy according to serum CA-125 J Clin Oncol 14 1996 1545 1551
13. R.T. Penson, F. Dignan, M.V. Seiden Attitudes to chemotherapy in patients with ovarian cancer Gynecol Oncol 94 2004 427 435
14. K.A. Donovan, P.G. Greene, J.L. Shuster Treatment preferences in recurrent ovarian cancer Gynecol Oncol 868 2002 200 211
15. A.R. Munkarah, R.L. Coleman Critical evaluation of secondary cytoreduction in recurrent ovarian cancer Gynecol Oncol 95 2004 273 280
16. E.A. Eisenhauer, J.B. Vermorken, M. van Glabbeke Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer A multivariate analysis of 704 patients Ann Oncol 8 1997 963 968
17. M. Gore Treatment of relapsed epithelial ovarian cancer M.C. Perry American Society of Clinical Oncology 2001 Educational Book 2001 American Society of Clinical Oncology Alexandria, VA 468 476
18. P.G. Rose, N. Fusco, L. Fluellen Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma J Clin Oncol 16 1998 1494 1497
19. A. du Bois, H.J. Lück, J. Pfisterer Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer-A dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group Ann Oncol 12 2001 1115 1120
20. C.A. Papadimitriou, G. Fountzilas, G. Aravantinos Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group study Gynecol Oncol 92 2004 152 159
21. J.-M. Ferrero, B. Weber, D. Lepille Carboplatin (PA) and pegylated liposomal doxorubicin (CA; PACA regimen) in patients with advanced ovarian cancer in late (>6 months) relapse (AOCLR) Survival results of a GINECO phase II trial Proc Am Soc Clin Oncol 23 2004 453 (abstr 5022)
22. D.S. Dizon, M.L. Hensley, E.A. Poyner Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma Application toward a dynamic disease state model of ovarian cancer J Clin Oncol 20 2002 1238 1247
23. J.T. Thigpen, J.A. Blessing, H. Ball Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy A Gynecologic Oncology Group study J Clin Oncol 12 1994 1748 1753
24. R.F. Ozols The role of gemcitabine in the treatment of ovarian cancer Semin Oncol 27 suppl 2 2000 40 47
25. S.A. Cannistra Is there a 'best' choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer? J Clin Oncol 20 2002 1158 1160
26. R.F. Ozols Recurrent ovarian cancer Evidence-based treatment J Clin Oncol 20 2002 1161 1163
27. A.N. Gordon, J.T. Fleagle, D. Guthrie Recurrent epithelial ovarian carcinoma A randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 2001 3312 3322
28. S.W. Hansen, H. Anderson, K. Boman Gemcitabine, carboplatin, paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB-IV Proc Am Soc Clin Oncol 18 1999 357 (abstr 1379)
29. K.Y. Look, M.A. Bookman, J. Schol Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer A Gynecologic Oncology Group study Gynecol Oncol 92 2004 93 100
30. J.P. Micha, B.H. Goldstein, M.A. Rettenmaier Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer Gynecol Oncol 94 2004 719 724